12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AllerT: Phase IIb started

Anergis began the double-blind, placebo-controlled, European Phase IIb AN004T trial to evaluate 2 dose levels of subcutaneous AllerT given on days 1, 7,...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >